Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Thoracic 1Myeloid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1

Interventions

Specimen Handling 629pembrolizumab 559Magnetic Resonance Spectroscopy 539Carboplatin 423Cyclophosphamide 371Cisplatin 371Biopsy 357Paclitaxel 304Nivolumab 301Gemcitabine 299Radiotherapy 270Bevacizumab 238Dexamethasone 207fludarabine 205Docetaxel 189durvalumab 178atezolizumab 176Oxaliplatin 172Fluorouracil 167venetoclax 164Rituximab 164Pemetrexed 162Radiation 159Doxorubicin 159Capecitabine 158Radiosurgery 147Etoposide 137Ipilimumab 134Leucovorin 133Lenalidomide 130

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
itacitinib × 90 days × Clear all
NCT05364762 2026-06-03

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

City of Hope Medical Center

Phase 2 Active not recruiting
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT01905813 2026-05-11

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Incyte Corporation

Phase 1 Completed
121 enrolled
Lymphoid

B-cell Malignancies

NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT02257619 2026-04-21

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Incyte Corporation

Phase 2 Terminated
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05757219 2026-03-31

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡